These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26131363)

  • 1. Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review.
    Bienz M; Saad F
    Bonekey Rep; 2015; 4():716. PubMed ID: 26131363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Joseph JS; Lam V; Patel MI
    Eur Urol Oncol; 2019 Sep; 2(5):551-561. PubMed ID: 31411986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review.
    Kim TJ; Koo KC
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32532121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer.
    Takahashi S
    J Bone Miner Metab; 2023 May; 41(3):307-316. PubMed ID: 37036530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
    Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
    Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
    Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.
    Mohamad NV; Soelaiman IN; Chin KY
    Endocr Metab Immune Disord Drug Targets; 2017 Nov; 17(4):276-284. PubMed ID: 28925899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer.
    Higano CS
    Urol Oncol; 2003; 21(5):392-8. PubMed ID: 14670551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
    Schulman C; Irani J; Aapro M
    BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of bone loss in men with prostate cancer.
    Higano CS
    J Urol; 2003 Dec; 170(6 Pt 2):S59-63; discussion S64. PubMed ID: 14610412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy.
    Pérez Ruixo JJ; Zheng J; Mandema JW
    J Clin Pharmacol; 2014 May; 54(5):503-12. PubMed ID: 24214315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing bone complications in prostate cancer.
    Bishr M; Saad F
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):299-303. PubMed ID: 22871982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes.
    Ahmadi H; Daneshmand S
    Patient Relat Outcome Meas; 2014; 5():63-70. PubMed ID: 25045284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation therapy for prostate cancer results in significant loss of bone density.
    Wei JT; Gross M; Jaffe CA; Gravlin K; Lahaie M; Faerber GJ; Cooney KA
    Urology; 1999 Oct; 54(4):607-11. PubMed ID: 10510915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
    Kiratli BJ; Srinivas S; Perkash I; Terris MK
    Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
    Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
    Daniell HW
    Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: A comprehensive review.
    Sharma A; Sinha RJ; Singh V; Garg G; Agarwal S; Pandey S
    Turk J Urol; 2019 Jul; 45(4):245-253. PubMed ID: 30817274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.